

FORM FOR NOTIFICATION OF PARTICIPATION AND POSTAL VOTING AT EXTRAORDINARY GENERAL MEETING ON 9 NOVEMBER 2023

This form must be received by ExpreS2ion Biotech Holding AB no later than **3 November 2023**.

Note that shareholders **whose shares are nominee-registered must register the shares in their own name in order to vote**. Shareholders should inform their nominees well in advance before 3 November 2023. Instructions for this can be found in the notice of the Extraordinary General Meeting.

The shareholder set out below hereby notifies the company of its participation and exercises its voting right for all of the shareholder's shares in ExpreS2ion Biotech Holding AB, reg. no. 559033-3729, at the Extraordinary General Meeting on 9 November 2023. The voting right is exercised in accordance with the voting options marked below.

Name of shareholder	Personal ID number / date of birth/Registration number
----------------------------	---

Assurance (if the undersigned is a legal representative of a shareholder who is a legal entity): I, the undersigned, am a board director, the CEO or a signatory of the shareholder and solemnly declare that I am authorized to submit this postal vote on behalf of the shareholder and that the contents of the postal vote correspond to the shareholder's decisions.

Assurance (if the undersigned represents the shareholder by proxy): I, the undersigned, solemnly declare that the enclosed power of attorney corresponds to the original and that it has not been revoked.

Telephone number	Telephone number
Place and date	
Signature*	
Clarification of signature	

* In case of signing on behalf of a legal entity, the name of the signatory shall be printed next to the signature and an up-to-date certificate of registration (or a similar document) shall be attached to the proxy form.

Instructions:

- Complete all the requested information above
- Select the preferred voting options below regarding how the shareholder wishes to vote
- Print, fill in, sign and send the form in original to ExpreS2ion Biotech Holding AB, "EGM 2023", c/o Mindpark, Rönnowsgatan 8C, 252 25 Helsingborg, Sweden. The completed and signed form may also be submitted electronically by e-mail to investor@expres2ionbio.com (with reference "EGM 2023").

- If the shareholder is a natural person who is personally voting in advance, it is the shareholder who should sign under Signature above. If the advance vote is submitted by a proxy of the shareholder, it is the proxy who should sign. If the advance vote is submitted by a legal representative of a legal entity, it is the representative who should sign.
- A power of attorney shall be enclosed if the shareholder votes in advance by proxy. If the shareholder is a legal entity, a registration certificate or a corresponding document for the legal entity shall be enclosed with the form.

Further information regarding postal voting

The board of directors of ExpreS2ion Biotech Holding AB has, in accordance with the company's articles of association, resolved that the shareholders of ExpreS2ion Biotech Holding AB, at the Extraordinary General Meeting on 9 November 2023 shall be able to exercise their voting rights by postal voting.

Shareholders cannot give any other instructions than selecting one of the voting options specified at each item in the form. If a shareholder wishes to abstain from voting in relation to a matter, please refrain from selecting a voting option. A vote (i.e. the postal vote in its entirety) is invalid if the shareholder has provided the form with specific instructions or conditions or if pre-printed text is amended or supplemented.

Only one form per shareholder will be considered. If more than one form is submitted, the form with the latest date will be considered. The form latest received by the company will be considered if two forms are dated at the same date. An incomplete or wrongfully completed form, or a form without valid authorisation documentation, may be discarded without being considered.

The postal voting form must be received by the company no later than 3 November 2023. A postal vote can be withdrawn up to and including 3 November 2023 by contacting the company by e-mail to investor@expres2ionbio.com (with reference "EGM 2023") or by post to ExpreS2ion Biotech Holding AB, "EGM 2023", c/o Mindpark, Rönnowsgatan 8C, 252 25 Helsingborg, Sweden, att: Keith Alexander.

For complete resolutions and proposals for resolutions, please refer to the notice and the other documents to the Extraordinary General Meeting on the company's website. The resolutions and the proposed resolutions set out in the notice and other documents to the Extraordinary General Meeting may be changed or withdrawn. ExpreS2ion Biotech Holding AB will disclose such adjustments through a press release, after which the shareholders have the right to submit a new form.

For information on how your personal data is processed, see the integrity policy that is available at Euroclear's website <https://www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammengelska.pdf>.

Extraordinary general meeting in ExpreS2ion Biotech Holding AB on 9 November 2023

The options below comprise the proposals submitted by the board of directors which are included in the notice convening the extraordinary general meeting.

The voting list proposed to be approved under item 2 below is the voting list prepared by the company, based on the shareholders' register on the record date of the general meeting and the advance votes received, and as verified by the person elected to attest the minutes.

The tasks of the person elected to approve the minutes also include verifying the voting list and that the advance votes received are correctly reflected in the minutes.

2. Preparation and approval of voting list Yes <input type="checkbox"/> No <input type="checkbox"/>
4. Determination of whether the meeting has been duly convened Yes <input type="checkbox"/> No <input type="checkbox"/>
5. Approval of the agenda Yes <input type="checkbox"/> No <input type="checkbox"/>
6. Resolution regarding incentive program 2023/2026 for senior executives and employees through issuance of warrants and approval of transfer of warrants Yes <input type="checkbox"/> No <input type="checkbox"/>